Skip to main content
. 2019 Apr 13;79(7):733–750. doi: 10.1007/s40265-019-01086-0

Table 2.

Pharmacokinetic profile of teneligliptin in special populations

Dose (mg/day) n Cmax (ng/mL)a AUC (ng·h/mL)a t½ (h)a Ratio to normal subjects (90% CI)b
C max AUC t ½
Renal impairment [34]
 Normal 20 8 176.50 (38.42) 1772.7 (657.3) 26.1 (5.0)
 Mild 20 8 207.96 (53.31) 2234.2 (278.6) 27.7 (7.9) 1.08 (0.86, 1.35) 1.25 (1.01, 1.54) 1.00 (0.76, 1.31)
 Moderate 20 8 203.63 (42.33) 3090.3 (868.6) 36.0 (11.0) 1.12 (0.89, 1.40) 1.68 (1.36, 2.07) 1.36 (1.04, 1.79)
 Severe 20 8 191.63 (49.07) 2833.3 (652.3) 29.8 (11.0) 1.04 (0.82, 1.32) 1.49 (1.19, 1.86) 1.02 (0.77, 1.37)
Renal impairment with ESRD [34]
 Normal 20 8 195.75 (43.28) 1843.1 (450.0) 18.3 (5.7)
 Pre-dialysis 20 8 164.45 (78.85) 2162.5 (488.1) 22.7 (7.7) 0.85 (0.64, 1.13) 1.17 (0.94, 1.47) 1.19 (0.89, 1.59)
 Post-dialysis 20 8 219.00 (118.91) 2472.9 (599.7) 23.6 (5.8) 1.10 (0.82, 1.46) 1.32 (1.06, 1.65) 1.31 (0.98, 1.75)
Hepatic impairment [36]
 Normal 20 8 185.88 (84.65) 1548.8 (209.1) 24.8 (6.4)
 Mild 20 8 229.25 (86.16) 2207.9 (790.0) 27.9 (7.1) 1.25 (0.97, 1.62) 1.46 (1.22, 1.74) 1.22 (0.94, 1.57)
 Moderate 20 8 247.63 (112.95) 2418.9 (505.8) 30.9 (6.6) 1.38 (1.07, 1.78) 1.59 (1.33, 1.90) 1.38 (1.07, 1.78)
Age (years) [31]
 ≥ 45 to < 65 20 12 143.6c 1637.6c 33.8c
 ≥ 65 to ≤ 75 20 12 142.7c 1502.8c 32.1c 1.01 (0.87, 1.16) 1.09 (0.98, 1.22) 1.05 (0.91, 1.22)

AUC area under the plasma concentration-time curve from time zero to infinity, Cmax maximal plasma concentration, ESRD end-stage renal disease, t½ elimination half-life, CI confidence interval

aMean (standard deviation)

bResults are reported as ratios of geometric means and the respective 90% CIs

cData are expressed as least square means as these were the only data available